The Current Opinion journals were developed out of the recognition that it is increasingly difficult for specialists to keep up to date with the expanding volume of information published in their subject. Elsevier’s Current Opinion journals comprise of 26 leading titles in life sciences and adjacent fields.

Current Opinion in Pharmacology

IMPACT FACTOR: 6.313
5-Year Impact Factor: 5.384
Issues per year: 6 issues
Editorial Board

Current Opinion in Pharmacology

The Current Opinion journals were developed out of the recognition that it is increasingly difficult for specialists to keep up to date with the expanding volume of information published in their subject. In Current Opinion in Pharmacology, we help the reader by providing in a systematic manner:
1. The views of experts on current advances in pharmacology in a clear and readable form.
2. Evaluations of the most interesting papers, annotated by experts, from the great wealth of original publications

Division of the subject into sections
The subject of pharmacology is divided into themed sections, each of which is reviewed once a year. The amount of space devoted to each section is related to its importance.

NeurosciencesCardiovascular and renalRespiratoryMusculoskeletalCancerImmunomodulationAnti-infectives • New technologiesGastrointestinalEndocrine and metabolic diseases

Selection of topics to be reviewed
Section Editors, who are major authorities in the field, are appointed by the Editors of the journal. They divide their section into a number of topics, ensuring that the field is comprehensively covered and that all issues of current importance are emphasised. Section Editors commission reviews from authorities on each topic that they have selected.

Reviews
Authors write short review articles in which they present recent developments in their subject, emphasising the aspects that, in their opinion, are most important. In addition, they provide short annotations to the papers that they consider to be most interesting from all those published in their topic over the previous year.

Editorial Overview
Section Editors write a short overview at the beginning of the section to introduce the reviews and to draw the reader's attention to any particularly interesting developments.

Ethics in Publishing: General Statement

The Editor(s) and Publisher of this Journal believe that there are fundamental principles underlying scholarly or professional publishing. While this may not amount to a formal 'code of conduct', these fundamental principles with respect to the authors' paper are that the paper should: i) be the authors' own original work, which has not been previously published elsewhere, ii) reflect the authors' own research and analysis and do so in a truthful and complete manner, iii) properly credit the meaningful contributions of co-authors and co-researchers, iv) not be submitted to more than one journal for consideration, and v) be appropriately placed in the context of prior and existing research. Of equal importance are ethical guidelines dealing with research methods and research funding, including issues dealing with informed consent, research subject privacy rights, conflicts of interest, and sources of funding. While it may not be possible to draft a 'code' that applies adequately to all instances and circumstances, we believe it useful to outline our expectations of authors and procedures that the Journal will employ in the event of questions concerning author conduct. With respect to conflicts of interest, the Publisher now requires authors to declare any conflicts of interest that relate to papers accepted for publication in this Journal. A conflict of interest may exist when an author or the author's institution has a financial or other relationship with other people or organizations that may inappropriately influence the author's work. A conflict can be actual or potential and full disclosure to the Journal is the safest course. All submissions to the Journal must include disclosure of all relationships that could be viewed as presenting a potential conflict of interest. The Journal may use such information as a basis for editorial decisions and may publish such disclosures if they are believed to be important to readers in judging the manuscript. A decision may be made by the Journal not to publish on the basis of the declared conflict.

For more information, please refer to: http://www.elsevier.com/conflictsofinterest

Best Cited over the last year.

Subscribe to RSS Sciverse Scopus

PD-1/PD-L1 inhibitors

Volume 23, Issue , 03 June 2015, Pp 32-38
Joel Sunshine | Janis M. Taube

Drugging PI3K in cancer: Refining targets and therapeutic strategies

Volume 23, Issue , 26 June 2015, Pp 98-107
Timothy A. Yap | Lynn Bjerke | Paul A. Clarke | Paul Workman

The NMDA receptor 'glycine modulatory site' in schizophrenia: D-serine, glycine, and beyond

Volume 20, Issue , 01 January 2015, Pp 109-115
Darrick T. Balu | Joseph T. Coyle

Parathyroid hormone: Anabolic and catabolic actions on the skeleton

Volume 22, Issue , 01 January 2015, Pp 41-50
Barbara C. Silva | John P. Bilezikian

NMDA receptor subunit mutations in neurodevelopmental disorders

Volume 20, Issue , 01 January 2015, Pp 73-82
Nail Burnashev | Pierre Szepetowski

PI3K inhibitors in inflammation, autoimmunity and cancer

Volume 23, Issue , 19 June 2015, Pp 82-91
Anne Katrien Stark | Srividya Sriskantharajah | Edith M. Hessel | Klaus Okkenhaug

Cachexia and sarcopenia: Mechanisms and potential targets for intervention

Volume 22, Issue , 13 June 2015, Pp 100-106
Josep M. Argilés | Silvia Busquets | Britta Stemmler | Francisco J. López-Soriano

Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome

Volume 20, Issue , 01 January 2015, Pp 124-134
Sebastian H. Scharf | Georg Jaeschke | Joseph G. Wettstein | Lothar Lindemann

Emerging targets in osteoarthritis therapy

Volume 22, Issue , 01 June 2015, Pp 51-63
Mary B. Goldring | Francis Berenbaum

Advances in the development of histone lysine demethylase inhibitors

Volume 23, Issue 1, 01 January 2015, Pp 52-60
Tamara Maes | Elena Carceller | Jordi Salas | Alberto Ortega | Carlos Buesa

An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies

Volume 24, Issue , 15 August 2015, Pp 52-58
Graham McClorey | Matthew J. Wood

Allosteric modulators of NMDA receptors: Multiple sites and mechanisms

Volume 20, Issue , 01 January 2015, Pp 14-23
Shujia Zhu | Pierre Paoletti

NMDA receptor dysfunction in autism spectrum disorders

Volume 20, Issue , 01 January 2015, Pp 8-13
Eun Jae Lee | Su Yeon Choi | Eunjoon Kim

Metabotropic glutamate receptors as drug targets: What's new?

Volume 20, Issue , 01 January 2015, Pp 89-94
Ferdinando Nicoletti | Valeria Bruno | Richard Teke Ngomba | Roberto Gradini | Giuseppe Battaglia

Excitatory amino acid transporters: Recent insights into molecular mechanisms, novel modes of modulation and new therapeutic possibilities

Volume 20, Issue , 01 January 2015, Pp 116-123
Anders A. Jensen | Christoph Fahlke | Walden E. Bjørn-Yoshimoto | Lennart Bunch

Immunosuppressive activities of adenosine in cancer

Volume 29, Issue , 01 August 2016, Pp 7-16
Bertrand Allard | Paul A. Beavis | Phillip K. Darcy | John Stagg

CSF-1/CSF-1R targeting agents in clinical development for cancer therapy

Volume 23, Issue , 04 June 2015, Pp 45-51
Carola H. Ries | Sabine Hoves | Michael A. Cannarile | Dominik Rüttinger

Astroglia dynamics in ageing and Alzheimer's disease

Volume 26, Issue , 01 February 2016, Pp 74-79
Alexei Verkhratsky | Robert Zorec | Jose J. Rodríguez | Vladimir Parpura

TRP channels

Volume 22, Issue , 01 January 2015, Pp 18-23
Silvia Benemei | Riccardo Patacchini | Marcello Trevisani | Pierangelo Geppetti

Adeno-associated virus serotypes for gene therapeutics

Volume 24, Issue , 22 August 2015, Pp 59-67
Leszek Lisowski | Szun Szun Tay | Ian Edward Alexander

How does ketamine elicit a rapid antidepressant response?

Volume 20, Issue , 01 January 2015, Pp 35-39
Ege T. Kavalali | Lisa M. Monteggia

YAP/TAZ as therapeutic targets in cancer

Volume 29, Issue , 01 August 2016, Pp 26-33
Francesca Zanconato | Giusy Battilana | Michelangelo Cordenonsi | Stefano Piccolo

CAV-2 - Why a canine virus is a neurobiologist's best friend

Volume 24, Issue , 22 August 2015, Pp 86-93
Felix Junyent | Eric J. Kremer

Role of T lymphocytes in hypertension

Volume 21, Issue , 01 April 2015, Pp 14-19
Jiandong Zhang | Steven D. Crowley